Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903101 | 0.90 | SIGMAR1 (0.51) | F2RFAAHGPR183MEN1KMT2A | |
| SCHEMBL2903083 | 0.90 | HTR2A (0.46) | F2R | |
| SCHEMBL2908869 | 0.89 | FAAH (0.51) | F2RFAAHGPR183MEN1KMT2A | |
| SCHEMBL2905713 | 0.89 | ALDH1A1 (0.46) | F2RFAAH | |
| SCHEMBL2909313 | 0.89 | FAAH (0.52) | F2RFAAHGPR183MEN1KMT2A | |
| SCHEMBL2904068 | 0.88 | LMNA (0.51) | FAAHMEN1KMT2AATM | |
| SCHEMBL2906156 | 0.87 | ALDH1A1 (0.52) | F2RFAAHGPR183 | |
| SCHEMBL2906184 | 0.84 | ALDH1A1 (0.54) | FAAHGPR183MEN1KMT2AATM | |
| SCHEMBL2905724 | 0.84 | FAAH (0.53) | FAAHMEN1KMT2AATM | |
| SCHEMBL2906083 | 0.83 | SIGMAR1 (0.57) | FAAHMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2019-04-23 | — | — | US | claimed |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2018-11-01 | — | — | US | claimed |
| US-9980970-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2018-05-29 | — | — | US | claimed |
| EP-3082818-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | Pierre Fabre Médicament (FR) | 2016-10-26 | — | — | EP | claimed |
| US-20160287603-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2016-10-06 | — | — | US | claimed |
| WO-2016066789-A1 | USE OF PAR-1 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF PELVIC-PERINEAL FUNCTIONAL DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2016-05-06 | — | — | WO | claimed |
| WO-2015090705-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2015-06-25 | — | — | WO | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | claimed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | claimed |
| EP-2041104-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2007147824-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | claimed |
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2019-04-23 | — | — | US | disclosed |
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2019-04-23 | — | — | US | disclosed |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2018-11-01 | — | — | US | disclosed |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2018-11-01 | — | — | US | disclosed |
| US-8217046-B2 | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2012-07-10 | — | — | US | disclosed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2041104-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147824-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | F2R 1/4885FAAH 506/4885GPR183 891/4885 |
| US-20160287603-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | F2R, F2RL1, SERPINB1 | F2R 1/4885FAAH 687/4885GPR183 945/4885 |
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | F2R, F2RL1, SERPINB1 | F2R 1/4885FAAH 687/4885GPR183 945/4885 |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | F2R, F2RL1, SERPINB1 | F2R 1/4885FAAH 687/4885GPR183 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.